

IMPORTANT NEWS

ViiV Healthcare is going to support the PANNA network financially. This means that we will include **dolutegravir** in the list of medication to be investigated in PANNA. We will draft an amendment for this purpose and also will include **elvitegravir** and **cobicistat**.

The **abacavir** and **maraviroc** arm will be **closed** from now onwards.

Stein Schalkwijk (PhD student) has joined the PANNA team and will support Angela and David.

Centres

St Thomas Hospital, London, will be included as satellite site in the UK.

List of compounds under investigation, open now

panna

- Etravirine, Intelence, ETV
- Rilpivirine, Edurant, Eviplera
- Efavirenz, Stocrin, Atripla, EFV*
- Fosamprenavir, Telzir, FPV
- Tipranavir, Aptivus, TPV
- Indinavir, Crixivan, IDV
- Enfuvirtide, Fuzeon, T-20



*UK/Ireland only

After approval of the amendment in your hospital patients on dolutegravir, elvitegravir and cobicistat can be included. Please let Angela know in case you have an eligible patient for one of these compounds before approval of the amendment.

Closed arms:

Tenofovir, emtricitabine, atazanavir, darunavir, raltegravir, abacavir, maraviroc.

Inclusions



PUBLICATIONS AND PRESENTATIONS

CROI 2015

The joint abstract on etravirine data with IMPAACT has been accepted as poster presentation.

All PANNA investigators who attend CROI will be invited for dinner. We will keep you informed on the details.

The darunavir manuscript has been accepted by JAC, the raltegravir manuscript is still under review at Lancet Infectious Diseases.

We are working on a joint manuscript (with IMPAACT) on maraviroc and the abacavir paper will be written early 2015.

Angela will defend her thesis in 2015!

All the best for



Angela, Stein and David

Angela Colbers
Project manager

E-mail: Angela.Colbers@radboudumc.nl

Stein Schalkwijk

E-mail:

Stein.J.Schalkwijk@radboudumc.nl

Radboud university medical center,
Internal postal code 864, Department of
Pharmacy,

P.O. Box 9101, 6500 HB Nijmegen

Phone: + 31 (0)24 - 361 64 05

Fax: + 31 (0)24- 366 87 55